Clover Health Investments, Corp. Form 8-K Summary
Business Context and Reporting Period
Clover Health Investments, Corp. filed a Form 8-K reporting board appointments. The earliest reported event occurred on September 22, 2026; the filing was signed and dated September 24, 2026. The filing concerns corporate governance rather than quarterly or annual financial results.
Board Appointments and Compensation
- Senator Robert G. Torricelli was appointed as a Class I director and to the Audit Committee.
- Dr. Brian J. Miller, M.D., M.B.A., M.P.H. was appointed as a Class III director and to the Clinical Committee.
- The appointments fill two previously disclosed vacancies, bringing the Board to nine directors.
- Each director will receive a pro rata portion of applicable 2026 annual board and committee retainers under Clover’s amended director compensation policy.
- Each director will receive a pro-rated restricted stock unit award with a stated annual RSU value of $200,000, based on service from appointment through December 31, 2026.
- Each director will enter into Clover’s standard indemnification agreement, including expense advancement provisions.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating or financial performance metrics.
Material Changes, Outlook, and Risks
The principal disclosed change is the expansion of the Board to nine directors and the assignment of the new directors to the Audit and Clinical Committees. The filing provides no new business outlook or financial guidance.
The directors’ compensation, equity awards, and indemnification obligations represent the principal disclosed financial and legal commitments. The filing states that neither director has a reportable material interest under Item 404(a) of Regulation S-K, a family relationship with Clover’s directors or executive officers, or an arrangement with another person regarding selection as a director.
Important Facts to Verify
- Confirm the effective appointment date and the distinction between the September 22 event date and the September 24 filing and press-release dates.
- Review the attached Exhibit 99.1 press release for additional biographical or governance commentary.
- Verify the final pro-rated value and vesting terms of each director’s RSU award.
- Review Clover’s Amended and Restated Director Compensation Policy and standard indemnification agreement for complete compensation and liability terms.
- Assess whether the new Audit and Clinical Committee memberships affect committee expertise, independence, or future governance disclosures.